Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26 According to Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has received a consensus rating of “Buy” from the twenty ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $309.26.

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $300.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, September 25th. UBS Group reaffirmed a “buy” rating and set a $269.00 target price (down from $307.00) on shares of Ascendis Pharma A/S in a report on Thursday, October 15th. HC Wainwright set a $344.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Oppenheimer lifted their price target on shares of Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 1st. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jean-Jacques Bienaimé purchased 2,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $246.33 per share, with a total value of $492,660.00. Following the acquisition, the director directly owned 2,900 shares of the company’s stock, valued at $714,357. This trade represents a 222.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC raised its position in shares of Ascendis Pharma A/S by 41.6% during the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares during the period. Pictet Asset Management Holding SA lifted its stake in shares of Ascendis Pharma A/S by 243.0% during the 1st quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock valued at $56,907,000 after buying an additional 178,415 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $26,837,000. Troluce Capital Advisors LLC bought a new position in Ascendis Pharma A/S in the 1st quarter worth $22,782,000. Finally, Sapient Capital LLC bought a new position in Ascendis Pharma A/S in the 2nd quarter worth $24,581,000.

Ascendis Pharma A/S Trading Up 0.2%

Shares of NASDAQ:ASND opened at $243.37 on Wednesday. The stock’s 50-day simple moving average is $243.04 and its two-hundred day simple moving average is $242.79. The stock has a market capitalization of $15.18 billion, a price-to-earnings ratio of 18.88 and a beta of 0.38. Ascendis Pharma A/S has a 52-week low of $188.07 and a 52-week high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The business had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Analysts expect that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.